Alfasigma

Bologna, Italy Founded: 2015 • Age: 11 yrs
Generic tablets, capsules, syrups, and injectables are manufactured.

About Alfasigma

Alfasigma is a Healthcare company based in Bologna (Italy) founded in 2015. Generic tablets, capsules, syrups, and injectables are manufactured. Alfasigma has completed 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca and Pamlab. Its chief executive, as recorded, is Bryan Downey. Its website alfasigma.com draws about 55 thousand monthly visits. Its Indian entity Alfasigma India Private Limited reported revenue of β‚Ή90 Lakh. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Alfasigma was established in 2015 and is based in Bologna, Italy, within the pharmaceutical sector. Finished generic formulations, including tablets, capsules, syrups, and injectables, are produced by the company. Operations focus on key products such as rifaximin, carnitine, sulodexide, and parnaparin, supporting generic drug distribution across various markets.

  • Headquarters Bologna, Italy
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website alfasigma.com
  • Social LinkedIn
  • Legal Name Alfasigma India Private Limited
  • Date of Incorporation 06 Aug, 2008
  • Jurisdiction Mumbai, Maharashtra, India
Key Metrics
  • Indian entity revenue
    ₹90 Lakh

    FY 2022 · +4% YoY

  • Indian entity net loss
    -₹31.6 Lakh

    FY 2022 · -35% margin

  • Latest Funding Round
    $176.07M (USD), Debt – Conventional

    Jul 2025

  • Investors
    BPER Banca

    & 1 more

  • Investments & Acquisitions

Funding Insights of Alfasigma

  • Total Rounds 2
  • Last Round Debt – Conventional β€” $176.07M
  • First Round $169.66M

    (May 2025)

  • Investors Count 2

All 2 funding rounds of Alfasigma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2025$176.07MDebt – Conventional––
May 2025$169.66MDebt – Conventional––
Valuation history

2 investors in total: 2 institutional.

Investors in Alfasigma

Alfasigma has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include BPER Banca and European Investment Bank.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Finance and advisory services for infrastructure projects are provided.
1958eib.orgLuxembourg, Luxembourg
Regional banking and investment services are provided to various clients.
1867bper.itModena, Italy
Premium access

Investor details for Alfasigma

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Alfasigma India Private Limited (Alfasigma)

Alfasigma India Private Limited is the primary company behind Alfasigma. The board of Alfasigma India Private Limited currently have 4 directors; the longest-serving is Stefano Pasi, appointed in 2016. 10 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Stefano Pasi
DIN 07470451
Director15 Mar 201610 yrs 8 moAlfasigma India Private Limited
Giuseppe Allocca
DIN 08909639
Director08 Oct 20206 yrs 1 moAlfasigma India Private Limited
Kumar Krishnan Iyer
DIN 00034834
Director01 Mar 20233 yrs 8 moAlfasigma India Private Limited
Rakesh Maganlal Nathwani
DIN 00141935
IRP/RP/Liquidator18 Dec 20232 yrs 11 moAlfasigma India Private Limited

People of Alfasigma

1 people are tracked at Alfasigma (1 in leadership).

NameRoleGroup
Bryan Downey
CEO & PresidentLeadership
Premium access

Complete people profiles for Alfasigma

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Alfasigma

Figures of Alfasigma India Private Limited, the primary company behind Alfasigma, for FY 2022. Revenue was ₹90 Lakh (+4% year on year). Net loss was -₹31.6 Lakh (-35% margin). Revenue has grown at a compounded annual rate of +12% over three years.

  • ₹90 LakhRevenue · FY 2022 · +4% YoY
  • -₹31.6 LakhNet loss · -35% margin
  • ₹3.74 CrPaid-up capital
  • +12%Revenue CAGR, 3 years

Balance sheet, profit and loss, cash flow and ratios of Alfasigma India Private Limited are on its company page.

Premium access

Detailed financial statements for Alfasigma

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Alfasigma

Alfasigma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Intercept Pharmaceuticals, Jyseleca and Pamlab.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Drug information is provided through the Jyseleca website.
0Feb 2024β€’β€’β€’β€’
Developer of therapeutics to treat progressive non-viral liver diseases
interceptpharma.comNew York, United States2002Sep 2023$794M
Pharmaceutical finished products such as tablets and capsules are manufactured.
sofarfarm.itTrezzano Rosa, Italy1968Aug 2022β€’β€’β€’β€’
Pharmaceutical company providing prescription medical food
pamlab.comCovington, United States1957Jan 2017β€’β€’β€’β€’
Premium access

Complete acquisition details for Alfasigma

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Alfasigma

7 dated milestones of Alfasigma across 10 years, from founding to its latest funding, stage changes and deals.

  1. Founded Alfasigma is founded.
  2. Acquisition Acquires Pamlab.
  3. Acquisition Acquires Sofar.
  4. Acquisition Acquires Intercept Pharmaceuticals.
  5. Acquisition Acquires Jyseleca.
  6. Funding First funding round of $169.7M.
  7. Funding Latest funding round, Debt – Conventional, of $176.1M.

Web traffic of Alfasigma

The website of Alfasigma (alfasigma.com) receives about 55.2K visits a month and ranks #605,770 among all websites worldwide, #643 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    55.2K

    ▲ 12.1% vs previous month

  • Unique visitors
    21.2K

    per month

  • Global rank
    #605,770

    among all websites

  • Category rank
    #643

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Alfasigma. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
clinvest.ru
clinvest.ru
100%
#972,098–
labworld.it
96%
#1,872,223View details
acino.swiss
96%
8.5K#2,030,551View details
granfarmaciaonline.es
72%
#1,534,599View details
farmaciamarquesbraga.pt
farmaciamarquesbraga.pt
72%
#4,269,161–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 32 similar websites and full traffic analytics for Alfasigma

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 32 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Alfasigma

Alfasigma was founded in 2015 and raised its 1st funding round 10 years after it was founded.

Alfasigma is headquartered in Bologna, Italy. It is registered at Bologna, Emilia-romagna, Italy.

Bryan Downey is the CEO of Alfasigma, as recorded in our data.

The primary company behind Alfasigma, Alfasigma India Private Limited, reported revenue of β‚Ή90 Lakh for FY 2022, up 4% year on year.

Alfasigma was established in 2015 and is based in Bologna, Italy, within the pharmaceutical sector. Finished generic formulations, including tablets, capsules, syrups, and injectables, are produced by the company. Operations focus on key products such as rifaximin, carnitine, sulodexide, and parnaparin, supporting generic drug distribution across various markets.

Alfasigma has made 4 acquisitions, including Intercept Pharmaceuticals, Jyseleca, and Pamlab.

Alfasigma has 2 investors. Key investors include BPER Banca, and European Investment Bank.

Alfasigma operates through Alfasigma India Private Limited.

The legal entities of Alfasigma currently have 4 directors, including Giuseppe Allocca, Stefano Pasi, Kumar Krishnan Iyer and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available